Publication

Zika vaccines and therapeutics: landscape analysis and challenges ahead

The devastating consequences of Zika virus (ZIKV) infection, leading to congenital Zika syndrome (CZS) and neurological complications such as Guillain–Barre Syndrome (GBS), led the World Health Organization (WHO) to declare a Public Health Emergency of International Concern on February 1, 2016, and to call on the global research and product development (R&D) communities to prioritize the development of preventative and therapeutic solutions. The R&D communities responded rapidly, with 45 vaccine candidates being initially evaluated in non-clinical studies and most progressing to active development.